Answers are grounded in this paper and cite their sources.
Background: Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, yet few studies have reported the treatment outcomes, toxicity patterns and relapse rates in low- and middle-income countries. Aim: To investigate overall survival (OS) and toxicity patterns in children with ALL. Setting: The study took place at Tygerberg Hospital, South Africa. Methods: Data on demographics, disease, treatment, toxicity and outcome data were collected over ten years. Descriptive statistics and associations were calculated. Overall survival was estimated using Kaplan–Meier curves. Results: A total of 112 patients (male-to-female ratio 1:0.6) had a median age of 4.6 years (IQR 2.9–8.4). The 5-year OS was 65.7% (95% CI 56.0% – 74.6%), and the 5-year EFS was 64.8% (95% CI 55.0% – 73.8%). Standard-risk patients had higher 5-year OS of 74.4% (95% CI 57.9% – 87.0%) versus 60.9% (95% CI 48.4% – 72.4%) for high-risk patients. Most relapses (20.5%; n = 23) occurred in high-risk patients (82.6%, 19/23) (p = 0.049). Patients with Hyperleukocytosis (23%; n = 26) was linked to increased relapse risk (OR 5.0; 95% CI 1.5% – 17.5%; p = 0.026). Ten patients (8.9%) died while on maintenance treatment. Grade 3 and 4 haematological toxicity occurred in 18% and 19%, respectively. Delays in maintenance initiation occurred in 29% of patients, and 8% required blood product support. Conclusion: The OS in standard-risk ALL improved to 74.4%, while overall OS was 65.7%. Hyperleukocytosis at diagnosis was associated with increased relapse risk. Contribution: This study highlights the burden of haematological toxicity in South African children treated on a contemporary ALL regimen, with frequent treatment delays and need for blood product support.
No takes yet. Share an insight, caveat, or question.
Schoonraad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: